ICH E9 emphasizes the importance of a well-defined trial design. This includes specifying the primary endpoint, determining the appropriate sample size, and ensuring that the randomization process is robust. In cancer trials, this could mean careful consideration of endpoints such as overall survival or progression-free survival, and ensuring that the study is adequately powered to detect clinically meaningful differences.
